ASX Announcement

15 December 2023

RHYTHM BIOSCIENCES

Receipt of Notice under Section 249D of the Corporations Act

Rhythm Biosciences Ltd (ASX: RHY) ("Rhythm" or the "Company") in accordance with ASX Listing Rule 3.17A announces that yesterday afternoon the Company received a request from shareholders purporting to hold greater than 5% of the shares in the Company, for the Company to call a shareholders meeting pursuant to s249D of the Corporations Act (Cth) 2001 (s249D Notice) to consider the removal of Mr. Otto Buttula as a director.

The s249D Notice request was received by the Company at 1.58 pm on 14 December 2023. A copy of the notice received is attached.

The Board of Directors unanimously support Mr. Buttula and Director shareholders intend to vote their shares against the resolution. The Company will convene a shareholder's meeting within the prescribed period (likely to be held in early / mid-February 2024) and will provide a Notice of Meeting in due course.

As foreshadowed at the Company's 2023 AGM the Company is currently undertaking a strategic review – and further details of that review will be announced as soon as possible.

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr. Otto Buttula	Ms. Andrea Steele
Executive Chairman	General Counsel & Company Secretary

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Rhythm Biosciences Ltd ACN 619 459 335 ASX: RHY

Australian Registered Address Bio21 Molecular Science & Biotechnology Institute 30 Flemington Road Parkville VIC 3010 Australia

Directors Otto Buttula Sue MacLeman Trevor Lockett Rachel David Louis Panaccio

Executive Chairman Independent Deputy Chair **Executive Director** Non-Executive Director Non-Executive Director

www.rhythmbio.com

+61 3 8256 2880 Е info@rhythmbio.com

т

The Directors Rhythm Biosciences Limited Bio21 Institute, 30 Flemington Road Parkville VIC 3010

Request that the directors of Rhythm Biosciences Limited call and arrange to hold a general meeting under section 249D of the *Corporations Act 2001* (Cth)

Daniel and Julie Eddington <DJ HOLDINGS A/C>, JAWAF Enterprises Pty Ltd <Hall Family A/C>, Loumea Investments Pty Ltd and Richard Vom (together, the **Requisitioning Shareholders**) are members of Rhythm Biosciences Limited ACN 619 459 335 (**Company**) holding (as at midnight on 13 December 2023) an aggregate of 11,756,052 fully paid ordinary shares in the capital of the Company, being approximately 5.3% of the votes that may be cast at a general meeting of the Company.

Pursuant to section 249D of the *Corporations Act 2001* (Cth), the Requisitioning Shareholders request that the directors of the Company call and arrange to hold a general meeting of the Company (**General Meeting**) as soon as possible.

The business of that General Meeting is to consider, and if thought fit to pass, the following resolution as an ordinary resolution:

RESOLUTION 1 – REMOVAL OF DIRECTOR – OTTO BUTTULA

"That, pursuant to section 203D(1) of the Corporations Act 2001 (Cth), Otto Buttula be removed as a director of the Company effective immediately on the passing of this resolution."

We look forward to seeing the notice of general meeting sent out (**EGM**). If the EGM is not called and held in accordance with the timetable in section 249D then the Shareholders reserve their rights to call the EGM themselves under section 249E and recover the cost of doing so from the current directors.

Execution

Dated: 14 December 2023

Signed by **Daniel Eddington** (in his capacity as joint trustee for the DJ Holdings A/C) in the presence of:

Signature of Witness

Witness Name (print)

Signature of Daniel Eddington

Signed by Julie Eddington (in her capacity as joint trustee for the DJ Holdings A/C) in the presence of:

h' GM

Signature of Julie Eddington

Signature of Witness

EDDING CHRIS

Witness Name (print)

Executed by JAWAF Enterprises Pty Ltd (ACN 607 150 130) ATF <Hall Family A/C> under section 127(1) of the Corporations Act 2001 (Cth) by:

Signature of sole director

Full name of sole director

Executed by Loumea Investments Pty Ltd (ACN 616 538 384) under section 127(1) of the Corporations Act 2001 (Cth) by:

Signature of sole director

Richard Vom Full name of sole director

Signed by Richard Vom in the presence of:

Signature of Witness

Nicholas Belleville Witness Name (print)

Signature of Richard Vom

Signed by **Julie Eddington** (in her capacity as joint trustee for the DJ Holdings A/C) in the presence of:

Signature of Witness

Signature of Julie Eddington

Witness Name (print)

Executed by **JAWAF Enterprises Pty Ltd** (ACN 607 150 130) ATF <Hall Family A/C> under section 127(1) of the *Corporations Act 2001* (Cth) by:

Signature of sole director

Anthony Hall

Full name of sole director

Executed by **Loumea Investments Pty Ltd** (ACN 616 538 384) under section 127(1) of the *Corporations Act 2001* (Cth) by:

Signature of sole director

Full name of sole director

Signed by Richard Vom in the presence of:

Signature of Witness

Signature of Richard Vom

Witness Name (print)